Tags

Type your tag names separated by a space and hit enter

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Biol Psychiatry. 2009 Sep 15; 66(6):603-13.BP

Abstract

BACKGROUND

Pharmacologic studies have implicated dopamine D1-like receptors in the development of dopamine precursor molecule 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesias and associated molecular changes in hemiparkinsonian mice. However, pharmacologic agents for D1 or D2 receptors also recognize other receptor family members. Genetic inactivation of the dopamine D1 or D2 receptor was used to define the involvement of these receptor subtypes.

METHODS

During a 3-week period of daily L-DOPA treatment (25 mg/kg), mice were examined for development of contralateral turning behavior and dyskinesias. L-DOPA-induced changes in expression of signaling molecules and other proteins in the lesioned striatum were examined immunohistochemically.

RESULTS

Chronic L-DOPA treatment gradually induced rotational behavior and dyskinesia in wildtype hemiparkinsonian mice. Dyskinetic symptoms were associated with increased FosB and dynorphin expression, phosphorylation of extracellular signal-regulated kinase, and phosphoacetylation of histone 3 (H3) in the lesioned striatum. These molecular changes were restricted to striatal areas with complete dopaminergic denervation and occurred only in dynorphin-containing neurons of the direct pathway. D1 receptor inactivation abolished L-DOPA-induced dyskinesias and associated molecular changes. Inactivation of the D2 receptor had no significant effect on the behavioral or molecular response to chronic L-DOPA.

CONCLUSIONS

Our results demonstrate that the dopamine D1 receptor is critical for the development of L-DOPA-induced dyskinesias in mice and in the underlying molecular changes in the denervated striatum and that the D2 receptor has little or no involvement. In addition, we demonstrate that H3 phosphoacetylation is blocked by D1 receptor inactivation, suggesting that inhibitors of H3 acetylation and/or phosphorylation may be useful in preventing or reversing dyskinesia.

Authors+Show Affiliations

Cajal Institute, Consejo Superior de Investigaciones Científicas and Centro de Investigación Biomédica en Red para Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19520364

Citation

Darmopil, Sanja, et al. "Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA-induced Dyskinesia and Histone Activation." Biological Psychiatry, vol. 66, no. 6, 2009, pp. 603-13.
Darmopil S, Martín AB, De Diego IR, et al. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry. 2009;66(6):603-13.
Darmopil, S., Martín, A. B., De Diego, I. R., Ares, S., & Moratalla, R. (2009). Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biological Psychiatry, 66(6), 603-13. https://doi.org/10.1016/j.biopsych.2009.04.025
Darmopil S, et al. Genetic Inactivation of Dopamine D1 but Not D2 Receptors Inhibits L-DOPA-induced Dyskinesia and Histone Activation. Biol Psychiatry. 2009 Sep 15;66(6):603-13. PubMed PMID: 19520364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. AU - Darmopil,Sanja, AU - Martín,Ana B, AU - De Diego,Irene Ruiz, AU - Ares,Sara, AU - Moratalla,Rosario, Y1 - 2009/06/11/ PY - 2009/02/12/received PY - 2009/04/07/revised PY - 2009/04/17/accepted PY - 2009/6/13/entrez PY - 2009/6/13/pubmed PY - 2009/11/10/medline SP - 603 EP - 13 JF - Biological psychiatry JO - Biol Psychiatry VL - 66 IS - 6 N2 - BACKGROUND: Pharmacologic studies have implicated dopamine D1-like receptors in the development of dopamine precursor molecule 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesias and associated molecular changes in hemiparkinsonian mice. However, pharmacologic agents for D1 or D2 receptors also recognize other receptor family members. Genetic inactivation of the dopamine D1 or D2 receptor was used to define the involvement of these receptor subtypes. METHODS: During a 3-week period of daily L-DOPA treatment (25 mg/kg), mice were examined for development of contralateral turning behavior and dyskinesias. L-DOPA-induced changes in expression of signaling molecules and other proteins in the lesioned striatum were examined immunohistochemically. RESULTS: Chronic L-DOPA treatment gradually induced rotational behavior and dyskinesia in wildtype hemiparkinsonian mice. Dyskinetic symptoms were associated with increased FosB and dynorphin expression, phosphorylation of extracellular signal-regulated kinase, and phosphoacetylation of histone 3 (H3) in the lesioned striatum. These molecular changes were restricted to striatal areas with complete dopaminergic denervation and occurred only in dynorphin-containing neurons of the direct pathway. D1 receptor inactivation abolished L-DOPA-induced dyskinesias and associated molecular changes. Inactivation of the D2 receptor had no significant effect on the behavioral or molecular response to chronic L-DOPA. CONCLUSIONS: Our results demonstrate that the dopamine D1 receptor is critical for the development of L-DOPA-induced dyskinesias in mice and in the underlying molecular changes in the denervated striatum and that the D2 receptor has little or no involvement. In addition, we demonstrate that H3 phosphoacetylation is blocked by D1 receptor inactivation, suggesting that inhibitors of H3 acetylation and/or phosphorylation may be useful in preventing or reversing dyskinesia. SN - 1873-2402 UR - https://www.unboundmedicine.com/medline/citation/19520364/Genetic_inactivation_of_dopamine_D1_but_not_D2_receptors_inhibits_L_DOPA_induced_dyskinesia_and_histone_activation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-3223(09)00509-5 DB - PRIME DP - Unbound Medicine ER -